Families Hit Back At GSK'S Zofran Fraud Dismissal Bid

Law360, New York (January 4, 2017, 2:14 PM EST) -- Plaintiffs in a multidistrict litigation against GlaxoSmithKline PLC told a Massachusetts federal court Tuesday that they adequately set out off-label fraud claims in master complaints linking the anti-nausea drug Zofran to birth defects.

Although the master complaints lack granular detail about the alleged fraud, they lay out exactly what is needed at this stage in the MDL, which involves hundreds of people claiming their babies were injured or died as a result of prenatal exposure to the drug, according to the parents' opposition brief.

The filing...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In Re: Zofran (Ondansetron)Products Liability Litigation


Case Number

1:15-md-02657

Court

Massachusetts

Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Judge

F. Dennis Saylor, IV

Date Filed

October 13, 2015

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.